Drug Approval | October 01, 2025
AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
The platform is being introduced to expand access to treatments for people living with chronic conditions
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Miels will formally assume the role on January 1, 2026
The Hub & Spoke model is designed to extend advanced medical care to a wider community
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Subscribe To Our Newsletter & Stay Updated
